Angiopoietin-like 4

Angiopoietin-like 4

Angiopoietin-like 4 Informations sur la molécule

Molecule Name
Angiopoietin-related protein 4
Alias de la molécule
ANGPTL4,ARP4,FIAF,HFARP,PGAR,pp1158,Angiopoietin like 4
Drug Development Progress
Nombre de médicaments cliniques3
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
Angiopoietin-like protein 4,Hepatic fibrinogen/angiopoietin-related protein,HFARP,ARP4,PGAR,PP1158,PSEC0166,UNQ171/PRO197,Angiopoietin Like 4,Hepatic Fibrinogen/Angiopoietin-Related Protein,Angiopoietin-Related Protein 4,Pp1158,FIAF,NL2,Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Induced Angiopoietin-Related Protein,Hepatic Angiopoietin-Related Protein,PPARG Angiopoietin Related Protein,Fasting-Induced Adipose Factor,Angiopoietin-Like Protein 4,Angiopoietin-Like 4,UNQ171,TGQTL,HARP
Contexte de la molécule
Angiopoietin-related protein 4 (ANGPTL4) is also known as Hepatic fibrinogen / angiopoietin - related protein (HFARP), ARP4, PGAR. ANGPTL4 contains one fibrinogen C-terminal domain. ANGPTL4 is a homooligomer , and the homooligomer undergoes proteolytic processing to release its carboxyl fibrinogen-like domain, which circulates as a monomer. The homooligomer unprocessed form is able to interact with the extracellular matrix. ANGPTL4 may act as a regulator of angiogenesis and modulate tumorigenesis. ANGPTL4 inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. ANGPTL4 may exert a protective function on endothelial cells through an endocrine action.

Angiopoietin-like 4 Liste de produits

Species
  • Human(1)
Tag
  • His Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product NameEspèceHostStructurePurityActivitySize&PriceAdd to Cart
Angiopoietin-like 4
Human Angiopoietin-like 4 / ANGPTL4 (166-406) Protein, His Tag
Human
HEK293
SDS-PAGE

$280.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
MAR001MAR001; MAR-001Phase 2 ClinicalMareas Therapeutic Services Inc
Hypertriglyceridemia
Details
LipisensePhase 1 ClinicalLipigon Pharmaceuticals AB, Secarna Pharmaceuticals GmbH & Co KG
Hypertriglyceridemia
Details
A24110HeA24110He; A-24110-HePhase 1 ClinicalLipigon Pharmaceuticals AB
Hyperlipidemias; Hypertriglyceridemia
Details
Customer Reviews